The Europe Ablation Technologies Market is expected to register a CAGR of nearly 5.2 % during the forecast period.
The COVID-19 pandemic affected healthcare systems and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. Moreover, catheter ablation procedures for atrial fibrillation (AF) were significantly curtailed during the peak of the COVID-19 pandemic to conserve healthcare resources and limit exposure. For instance, according to the study published by the National Library of Medicine, in January 2022, there were no cases of ablation-related COVID-19 transmission in the study population. As a result, fewer ablation procedures were performed, thereby negatively impacting the market. Thus, such circumstances greatly affected the market's growth rate throughout the initial pandemic phase. However, as the COVID-19 cases started to decline, the market started to show normal pre-pandemic level growth and is likely to continue its significant growth rate during the forecast period.
The factors propelling the studied market growth are the emergence of next-generation ablation products and technology and the growing burden of target diseases. For instance, an article published by the National Library of Medicine in June 2021 mentioned that the reported prevalence of cardiovascular diseases among patients with type 2 diabetes ranged from 6.9% to 40.8%. The prevalence of coronary heart disease ranged from 4.7 to 37%, stroke from 3.5 to 19.6%, peripheral artery disease from 2.5 to 13.0%, and heart failure from 4.3 to 20.1%. The high incidence of target diseases increases the demand for treatment, which, in turn, drives the market. Furthermore, the data published by the European Heart network in 2021 reported that in the European Union, more than 60 million people live with cardiovascular disease, and nearly 13 million new cases of cardiovascular diseases are diagnosed yearly. Such increasing prevalence of cardiovascular diseases, which led to an increasing need for treatment, is expected to drive the growth of the ablation technologies market.
Additionally, strategic initiatives such as product launches, mergers, acquisitions, partnerships, and others will lead to lucrative market growth. For instance, in January 2021, CardioFocus, Inc. expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal to launch of HeartLight X3 ablation system. The HeartLight X3 ablation system is a complement to the MicroPort EP range of catheters and the Columbus 3D imaging system. Such development is expected to drive the growth of the market over the forecast period.
Therefore, owing to the factors above, the studied market is expected to grow significantly during the study period. However, stringent regulatory scenarios and the high cost of devices are expected to hinder the market's growth during the forecast period.
Moreover, market players in Europe focus on growth strategies such as new product launches, partnerships, mergers, and acquisitions, which are driving the growth of the segment over the forecast period. For instance, in October 2022, Biosense Webster, Inc., part of Johnson & Johnson MedTech, launched HELIOSTAR Balloon Ablation Catheter, the first radiofrequency balloon ablation catheter in Europe. The HELIOSTAR Balloon Ablation Catheter is indicated for use in the catheter-based cardiac electrophysiological mapping (stimulating and recording) of the atria and, when used with a compatible multi-channel RF generator, for cardiac ablation. Such initiatives undertaken are expected to contribute to the growth of the segment.
Thus, the segment is expected to witness significant growth over the forecast period due to the abovementioned factors.
The technological advancements in ablation technologies, expansion, launches, and innovations by key market players in Germany are likely to boost segmental growth over the forecast period. For instance, in December 2022, TechsoMed Ltd. opened German Subsidiary as a strategic collaboration with the Research Institute Fraunhofer MEVIS, to accelerate end-to-end solutions for image-guided tumor ablation therapy. Such development is expected to drive the growth of the market over the forecast period.
Thus, given the factors above, the studied market is expected to grow significantly in Germany over the forecast period.
This product will be delivered within 2 business days.
The COVID-19 pandemic affected healthcare systems and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. Moreover, catheter ablation procedures for atrial fibrillation (AF) were significantly curtailed during the peak of the COVID-19 pandemic to conserve healthcare resources and limit exposure. For instance, according to the study published by the National Library of Medicine, in January 2022, there were no cases of ablation-related COVID-19 transmission in the study population. As a result, fewer ablation procedures were performed, thereby negatively impacting the market. Thus, such circumstances greatly affected the market's growth rate throughout the initial pandemic phase. However, as the COVID-19 cases started to decline, the market started to show normal pre-pandemic level growth and is likely to continue its significant growth rate during the forecast period.
The factors propelling the studied market growth are the emergence of next-generation ablation products and technology and the growing burden of target diseases. For instance, an article published by the National Library of Medicine in June 2021 mentioned that the reported prevalence of cardiovascular diseases among patients with type 2 diabetes ranged from 6.9% to 40.8%. The prevalence of coronary heart disease ranged from 4.7 to 37%, stroke from 3.5 to 19.6%, peripheral artery disease from 2.5 to 13.0%, and heart failure from 4.3 to 20.1%. The high incidence of target diseases increases the demand for treatment, which, in turn, drives the market. Furthermore, the data published by the European Heart network in 2021 reported that in the European Union, more than 60 million people live with cardiovascular disease, and nearly 13 million new cases of cardiovascular diseases are diagnosed yearly. Such increasing prevalence of cardiovascular diseases, which led to an increasing need for treatment, is expected to drive the growth of the ablation technologies market.
Additionally, strategic initiatives such as product launches, mergers, acquisitions, partnerships, and others will lead to lucrative market growth. For instance, in January 2021, CardioFocus, Inc. expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal to launch of HeartLight X3 ablation system. The HeartLight X3 ablation system is a complement to the MicroPort EP range of catheters and the Columbus 3D imaging system. Such development is expected to drive the growth of the market over the forecast period.
Therefore, owing to the factors above, the studied market is expected to grow significantly during the study period. However, stringent regulatory scenarios and the high cost of devices are expected to hinder the market's growth during the forecast period.
Europe Ablation Technologies Market Trends
Radiofrequency Ablation is Expected to Register a Significant Growth Rate over the Forecast Period
Radiofrequency ablation is a medical procedure in which part of the electrical conduction system of the heart, tumor, or other dysfunctional tissue is ablated using the heat generated from medium-frequency alternating current. The factors propelling the studied market growth are the increasing prevalence of minimally invasive procedures, the growing burden of chronic diseases, and the senior population. For instance, according to the British Heart Foundation England Factsheet, published in January 2022, about 6.4 million people are living with cardiovascular diseases in England. Also, as per the British Heart Foundation 2020 fact sheet, around 7.4 million people are living with heart and circulatory diseases in the United Kingdom. Thus, the rise in chronic diseases will significantly drive the growth of the studied market.Moreover, market players in Europe focus on growth strategies such as new product launches, partnerships, mergers, and acquisitions, which are driving the growth of the segment over the forecast period. For instance, in October 2022, Biosense Webster, Inc., part of Johnson & Johnson MedTech, launched HELIOSTAR Balloon Ablation Catheter, the first radiofrequency balloon ablation catheter in Europe. The HELIOSTAR Balloon Ablation Catheter is indicated for use in the catheter-based cardiac electrophysiological mapping (stimulating and recording) of the atria and, when used with a compatible multi-channel RF generator, for cardiac ablation. Such initiatives undertaken are expected to contribute to the growth of the segment.
Thus, the segment is expected to witness significant growth over the forecast period due to the abovementioned factors.
Germany is Expected to Show a Significant Share of the Market Over the Forecast Period
Germany is likely to grow in the ablation technologies market owing to factors such as the increasing burden of cardiovascular diseases. As per the German Heart Surgery Report 2021 statistics, in 2021, there were about 161,261 cardiac procedures performed in Germany out of 36,714 heart valve procedures, and 19,490 were pacemaker and ICD-related systems. Such a high number of cardiac procedures increases the demand for ablation devices in Germany.The technological advancements in ablation technologies, expansion, launches, and innovations by key market players in Germany are likely to boost segmental growth over the forecast period. For instance, in December 2022, TechsoMed Ltd. opened German Subsidiary as a strategic collaboration with the Research Institute Fraunhofer MEVIS, to accelerate end-to-end solutions for image-guided tumor ablation therapy. Such development is expected to drive the growth of the market over the forecast period.
Thus, given the factors above, the studied market is expected to grow significantly in Germany over the forecast period.
Europe Ablation Technologies Market Competitor Analysis
The Europe ablation technologies market is moderately concentrated in nature due to the presence of companies operating regionally. The major market players in the market include Boston Scientific Corporation, Conmed Corporation, Johnson & Johnson, Medtronic, Inc., Olympus Corporation, and Smith & Nephew PLC, among others.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Angiodynamics, Inc.
- Atricure, Inc.
- Johnson & Johnson
- Boston Scientific Corporation
- Conmed Corporation
- Medtronic, Inc.
- Olympus Corporation
- Smith & Nephew PLC
Methodology
LOADING...
